No evidence for adjuvant chemotherapy in high-risk disease

被引：1
作者：
Albers, Peter [1 ]
机构：
[1] Univ Hosp, Dept Urol, D-40225 Dusseldorf, Germany
来源：
NATURE REVIEWS UROLOGY | 2015年 / 12卷 / 11期
关键词：
PROSTATE-CANCER; ANDROGEN SUPPRESSION; TRIAL; RADIOTHERAPY; RADIATION; THERAPY; EORTC;
D O I：
10.1038/nrurol.2015.219
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
The RTOG trial investigated the survival benefit of chemotherapy combined with androgen deprivation therapy (ADT) in patients with high-risk nonmetastatic prostate cancer after radiotherapy. However, the 10-year overall survival data showed no difference between treatments; thus, chemotherapy is unlikely to improve the overall survival in patients with nonmetastatic prostate cancer.
引用
收藏
页码：602 / 603
页数：2
相关论文
共 9 条
[1]   Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer [J].
Albertsen, PC ;
Hanley, JA ;
Gleason, DF ;
Barry, MJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (11) :975-980
[2]   Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial [J].
Bolla, M ;
Collette, L ;
Blank, L ;
Warde, P ;
Dubois, JB ;
Mirimanoff, RO ;
Storme, G ;
Bernier, J ;
Kuten, A ;
Sternberg, C ;
Mattelaer, J ;
Torecilla, JL ;
Pfeffer, JR ;
Cutajar, CL ;
Zurlo, A ;
Pierart, M .
LANCET, 2002, 360 (9327) :103-108
[3]   Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911) [J].
Bolla, Michel ;
van Poppel, Hein ;
Tombal, Bertrand ;
Vekemans, Kris ;
Da Pozzo, Luigi ;
de Reijke, Theo M. ;
Verbaeys, Antony ;
Bosset, Jean-Francois ;
van Velthoven, Roland ;
Colombel, Marc ;
van de Beek, Cees ;
Verhagen, Paul ;
van den Bergh, Alphonsus ;
Sternberg, Cora ;
Gasser, Thomas ;
van Tienhoven, Geertjan ;
Scalliet, Pierre ;
Haustermans, Karin ;
Collette, Laurence .
LANCET, 2012, 380 (9858) :2018-2027
[4]   Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era [J].
D'Amico, AV ;
Moul, J ;
Carroll, PR ;
Sun, L ;
Lubeck, D ;
Chen, MH .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (11) :2163-2172
[5]   Androgen suppression plus radiation versus radiation alone for patients with stage D1/Pathologic node-positive adenocarcinoma of the prostate:: Updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31 [J].
Lawton, CA ;
Winter, K ;
Grignon, D ;
Pilepich, MV .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (04) :800-807
[6]  
Rosenthal S. A., INT J RAD ONCOL BIOL
[7]   PHASE III MULTI-INSTITUTIONAL TRIAL OF ADJUVANT CHEMOTHERAPY WITH PACLITAXEL, ESTRAMUSTINE, AND ORAL ETOPOSIDE COMBINED WITH LONG-TERM ANDROGEN SUPPRESSION THERAPY AND RADIOTHERAPY VERSUS LONG-TERM ANDROGEN SUPPRESSION PLUS RADIOTHERAPY ALONE FOR HIGH-RISK PROSTATE CANCER: PRELIMINARY TOXICITY ANALYSIS OF RTOG 99-02 [J].
Rosenthal, Seth A. ;
Bae, Kyoungwha ;
Pienta, Kenneth J. ;
Sobczak, Mark L. ;
Asbell, Sucha O. ;
Rajan, Raghu ;
Kerlin, Kevin J. ;
Michalski, Jeff M. ;
Sandler, Howard M. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 73 (03) :672-678
[8]  
Sandler HM, 2015, J CLIN ONCOL, V33
[9]   IS THERE EVIDENCE THAT CHEMOTHERAPY IS OF BENEFIT TO PATIENTS WITH CARCINOMA OF THE PROSTATE [J].
TANNOCK, IF .
JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (07) :1013-1021
1